Baxter Healthcare Corporation launched sevoflurane, the world's most widely-used inhaled anaesthetic, in China. The company plans for a phased launch of sevoflurane in additional geographies throughout 2006, including the United States, Japan and, upon regulatory approval, certain European markets.

Baxter's sevoflurane is chemically and therapeutically equivalent to Ultane (Abbott Laboratories). The addition of sevoflurane distinguishes Baxter as the only company that offers all three modern inhaled anaesthetics globally - sevoflurane, Suprane (desflurane, USP) and Forane (isoflurane, USP). In addition, Baxter offers the intravenous anaesthetic, propofol, in the United States, states a company release.

“With the addition of sevoflurane, Baxter now provides the broadest portfolio of inhaled anaesthetics to its customers worldwide. We will leverage our strong customer relationships and channels, along with investments we have made in sales and marketing, to successfully launch sevoflurane,” said Daniel Tassé, general manager of anaesthesia, critical care and oncology, part of Baxter's medication delivery business.

Inhaled anaesthetic agents such as sevoflurane are administered to patients through vaporiser machines. Baxter's sevoflurane is compatible with the same vaporisers as the branded product. In addition, to assure a seamless transition to the generic product, Baxter will offer customers access to vaporisers as part of a vaporizer placement programme, added the release.

Sevoflurane is indicated for induction and maintenance of general anaesthesia in adult and paediatric patients for inpatient and outpatient surgery.

Baxter's anaesthesia, critical care and oncology division develops, manufactures and markets specialty pharmaceutical products including inhaled anaesthetics, cardiovascular agents and a comprehensive line of multisource injectables.